Brief: Radiopharm Theranostics Achieves Primary Endpoint In 92% Of Patients At Interim Analysis Of Rad 101 Phase 2B Imaging Trial In Brain Metastases
15/12/2025 12:14
Dec 15 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS LTD: ACHIEVES PRIMARY ENDPOINT IN 92% OF PATIENTS AT INTERIM ANALYSIS OF RAD 101 PHASE 2B IMAGING TRIAL IN BRAIN METASTASES Source text: ID:nGNX3b9141 Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsNASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:50 AM